REGENXBIO

Seeking to improve lives through the curative potential of gene therapy

REGENXBIO’s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Status
NASDAQ: RGNX
Year of Investment
2020
Strategy
Life Sciences
Location
Rockville, Maryland